Galacto-oligosaccharides protect the intestinal barrier by maintaining the tight junction network and modulating the inflammatory responses after a challenge with the mycotoxin deoxynivalenol in human Caco-2 cell monolayers and B6C3F1 mice

Journal of Nutrition

Volumn 145, Issue 7, 2015, Pages 1604-1613

  Akbari, Peyman ^a   Braber, Saskia ^a   Alizadeh, Arash ^a   Verheijden, Kim A T ^a   Schoterman, Margriet H C ^b   Kraneveld, Aletta D ^a   Garssen, Johan ^a,c   Fink Gremmels, Johanna ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b FRIESLANDCAMPINA   (Netherlands)

^c Nutricia Nederland   (Netherlands)

Author keywords

Caco 2 cells; CXCL8; Deoxynivalenol; Galacto oligosaccharides; Intestinal integrity; Tight junction proteins

Indexed keywords

CLAUDIN 3; CXCL1 CHEMOKINE; EOSIN; GALACTOSE OLIGOSACCHARIDE; HEMATOXYLIN; INTERLEUKIN 8; LUCIFER YELLOW; MESSENGER RNA; TIGHT JUNCTION PROTEIN; VOMITOXIN; OLIGOSACCHARIDE; TRICHOTHECENE DERIVATIVE;

ACCELERATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACO 2 CELL LINE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; ELECTRIC RESISTANCE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; MALE; MONOLAYER CULTURE; MORPHOMETRICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; SYNTHESIS; TIGHT JUNCTION; TRANSEPITHELIAL ELECTRICAL RESISTANCE; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; PERMEABILITY;

MUS; TRITICUM AESTIVUM;

ANIMALS; CACO-2 CELLS; CLAUDIN-3; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-8; INTESTINAL MUCOSA; MALE; MICE; OLIGOSACCHARIDES; PERMEABILITY; TIGHT JUNCTIONS; TRICHOTHECENES;

EID: 84935444515     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.114.209486     Document Type: Article

References (66)

1. Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012;24:503-12. Erratum in: Neurogastroenterol Motil 2012;24:976.
2. Ménard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol 2010;3:247-59.
3. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009;124:3-20.
4. Pinton P, Tsybulskyy D, Lucioli J, Laffitte J, Callu P, Lyazhri F, Grosjean F, Bracarense AP, Kolf-Clauw M, Oswald IP. Toxicity of deoxynivalenol and its acetylated derivatives on the intestine: differential effects on morphology, barrier function, tight junction proteins, and mitogenactivated protein kinases. Toxicol Sci 2012;130:180-90.
5. Nossol C, Diesing AK, Kahlert S, Kersten S, Kluess J, Ponsuksili S, Hartig R, Wimmers K, Danicke S, Rothkotter HJ. Deoxynivalenol affects the composition of the basement membrane proteins and influences en route the migration of CD16(+) cells into the intestinal epithelium. Mycotoxin Res 2013;29:245-54.
6. Devreese M, Pasmans F, De Backer P, Croubels S. An in vitro model using the IPEC-J2 cell line for efficacy and drug interaction testing of mycotoxin detoxifying agents. Toxicol In Vitro 2013;27:157-63.
7. Diesing AK, Nossol C, Danicke S, Walk N, Post A, Kahlert S, Rothkotter HJ, Kluess J. Vulnerability of polarised intestinal porcine epithelial cells to mycotoxin deoxynivalenol depends on the route of application. PLoS ONE 2011;6:e17472.
8. Akbari P, Braber S, Gremmels H, Koelink PJ, Verheijden KA, Garssen J, Fink-Gremmels J. Deoxynivalenol: a trigger for intestinal integrity breakdown. FASEB J 2014;28:2414-29.
9. Sugita-Konishi Y, Park BJ, Kobayashi-Hattori K, Tanaka T, Chonan T, Yoshikawa K, Kumagai S. Effect of cooking process on the deoxynivalenol content and its subsequent cytotoxicity in wheat products. Biosci Biotechnol Biochem 2006;70:1764-8.
10. Pestka JJ. Deoxynivalenol: mechanisms of action, human exposure, and toxicological relevance. Arch Toxicol 2010;84:663-79.
11. Cano PM, Seeboth J, Meurens F, Cognie J, Abrami R, Oswald IP, Guzylack-Piriou L. Deoxynivalenol as a new factor in the persistence of intestinal inflammatory diseases: an emerging hypothesis through possible modulation of Th17-mediated response. PLoS ONE 2013; 8:e53647.
12. Pestka JJ. Deoxynivalenol: toxicity, mechanisms and animal health risks. Anim Feed Sci Technol 2007;137:283-98.
13. Pinton P, Oswald IP. Effect of deoxynivalenol and other type B trichothecenes on the intestine: a review. Toxins (Basel) 2014;6:1615-43.
14. Larsen JC, Hunt J, Perrin I, Ruckenbauer P. Workshop on trichothecenes with a focus on DON: summary report. Toxicol Lett 2004;153: 1-22.
15. Dänicke S, Brussow KP, Goyarts T, Valenta H, Ueberschar KH, Tiemann U. On the transfer of the Fusarium toxins deoxynivalenol (DON) and zearalenone (ZON) from the sow to the full-term piglet during the last third of gestation. Food Chem Toxicol 2007;45:1565-74.
16. Nielsen JK, Vikstrom AC, Turner P, Knudsen LE. Deoxynivalenol transport across the human placental barrier. Food Chem Toxicol 2011;49:2046-52.
17. Vos AP, M'Rabet L, Stahl B, Boehm G, Garssen J. Immune-modulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit Rev Immunol 2007;27:97-140.
18. Sangwan V, Tomar SK, Singh RR, Singh AK, Ali B. Galactooligosaccharides: novel components of designer foods. J Food Sci 2011;76:R103-11.
19. Vulevic J, Drakoularakou A, Yaqoob P, Tzortzis G, Gibson GR. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am J Clin Nutr 2008;88:1438-46.
20. Fanaro S, Marten B, Bagna R, Vigi V, Fabris C, Pena-Quintana L, Arguelles F, Scholz-Ahrens KE, Sawatzki G, Zelenka R, et al. Galactooligosaccharides are bifidogenic and safe at weaning: a double-blind randomized multicenter study. J Pediatr Gastroenterol Nutr 2009;48:82-8.
21. Ben XM, Zhou XY, Zhao WH, Yu WL, Pan W, Zhang WL, Wu SM, Van Beusekom CM, Schaafsma A. Supplementation of milk formula with galacto-oligosaccharides improves intestinal micro-flora and fermentation in term infants. Chin Med J (Engl) 2004;117:927-31.
22. Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y, Tanaka R, Otani T. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion 2011;84:128-33.
23. Fanaro S, Boehm G, Garssen J, Knol J, Mosca F, Stahl B, Vigi V. Galacto-oligosaccharides and long-chain fructo-oligosaccharides as prebiotics in infant formulas: a review. Acta Paediatr Suppl 2005;94:22-6.
24. Torres DPM, Goncalves MP, Teixeira JA, Rodrigues LR. Galactooligosaccharides: production, properties, applications, and significance as prebiotics. Comprehensive Reviews in Food Science and Food Safety 2010;9:438-54.
25. Coulier L, Timmermans J, Bas R, Van Den Dool R, Haaksman I, Klarenbeek B, Slaghek T, Van Dongen W. In-depth characterization of prebiotic galacto-oligosaccharides by a combination of analytical techniques. J Agric Food Chem 2009;57:8488-95.
26. Dombrink-Kurtzman MA, Poling SM, Kendra DF. Determination of deoxynivalenol in infant cereal by immunoaffinity column cleanup and high-pressure liquid chromatography-UV detection. J Food Prot 2010;73:1073-6.
27. Artursson P, Magnusson C. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J Pharm Sci 1990;79:595-600.
28. Reeves PG, Nielsen FH, Fahey GC, Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939-51.
29. Kinser S, Li M, Jia Q, Pestka JJ. Truncated deoxynivalenol-induced splenic immediate early gene response in mice consuming (n-3) polyunsaturated fatty acids. J Nutr Biochem 2005;16:88-95.
30. Moon Y, Pestka JJ. Cyclooxygenase-2 mediates interleukin-6 upregulation by vomitoxin (deoxynivalenol) in vitro and in vivo. Toxicol Appl Pharmacol 2003;187:80-8.
31. Azcona-Olivera JI, Ouyang Y, Murtha J, Chu FS, Pestka JJ. Induction of cytokine mRNAs in mice after oral exposure to the trichothecene vomitoxin (deoxynivalenol): relationship to toxin distribution and protein synthesis inhibition. Toxicol Appl Pharmacol 1995;133:109-20.
32. Moolenbeek C, Ruitenberg EJ. The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim 1981;15:57-9.
33. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146:1489-99.
34. Maresca M, Fantini J. Some food-associated mycotoxins as potential risk factors in humans predisposed to chronic intestinal inflammatory diseases. Toxicon 2010;56:282-94.
35. Van De Walle J, Romier B, Larondelle Y, Schneider YJ. Influence of deoxynivalenol on NF-κB activation and IL-8 secretion in human intestinal Caco-2 cells. Toxicol Lett 2008;177:205-14.
36. Sobrova P, Adam V, Vasatkova A, Beklova M, Zeman L, Kizek R. Deoxynivalenol and its toxicity. Interdiscip Toxicol 2010;3:94-9.
37. Wang Z, Wu Q, Kuca K, Dohnal V, Tian Z. Deoxynivalenol: signaling pathways and human exposure risk assessment-an update. Arch Toxicol 2014;88:1915-28.
38. Gnoth MJ, Rudloff S, Kunz C, Kinne RK. Investigations of the in vitro transport of human milk oligosaccharides by a Caco-2 monolayer using a novel high performance liquid chromatography-mass spectrometry technique. J Biol Chem 2001;276:34363-70.
39. Eiwegger T, Stahl B, Haidl P, Schmitt J, Boehm G, Dehlink E, Urbanek R, Szepfalusi Z. Prebiotic oligosaccharides: in vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties. Pediatr Allergy Immunol 2010;21:1179-88.
40. Goehring KC, Kennedy AD, Prieto PA, Buck RH. Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants. PLoS ONE 2014;9:e101692.
41. De Walle JV, Sergent T, Piront N, Toussaint O, Schneider YJ, Larondelle Y. Deoxynivalenol affects in vitro intestinal epithelial cell barrier integrity through inhibition of protein synthesis. Toxicol Appl Pharmacol 2010;245:291-8.
42. Azcona-Olivera JI, Ouyang YL, Warner RL, Linz JE, Pestka JJ. Effects of vomitoxin (deoxynivalenol) and cycloheximide on IL-2, 4, 5 and 6 secretion and mRNA levels in murine CD4+ cells. Food Chem Toxicol 1995;33:433-41.
43. Pinton P, Braicu C, Nougayrede JP, Laffitte J, Taranu I, Oswald IP. Deoxynivalenol impairs porcine intestinal barrier function and decreases the protein expression of claudin-4 through a mitogen-activated protein kinase-dependent mechanism. J Nutr 2010;140:1956-62.
44. Pinton P, Nougayrede JP, Del Rio JC, Moreno C, Marin DE, Ferrier L, Bracarense AP, Kolf-Clauw M, Oswald IP. The food contaminant deoxynivalenol decreases intestinal barrier permeability and reduces claudin expression. Toxicol Appl Pharmacol 2009;237:41-8.
45. Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 2001;120:411-22.
46. Patel RM, Myers LS, Kurundkar AR, Maheshwari A, Nusrat A, Lin PW. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol 2012;180:626-35.
47. Milatz S, Krug SM, Rosenthal R, Gunzel D, Muller D, Schulzke JD, Amasheh S, Fromm M. Claudin-3 acts as a sealing component of the tight junction for ions of either charge and uncharged solutes. Biochim Biophys Acta 2010;1798:2048-57.
48. Günzel D, Yu AS. Claudins and the modulation of tight junction permeability. Physiol Rev 2013;93:525-69.
49. Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 2013;4:280.
50. Mantis NJ, Rol N, Corthesy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 2011;4:603-11.
51. Johansson ME, Ambort D, Pelaseyed T, Schutte A, Gustafsson JK, Ermund A, Subramani DB, Holmen-Larsson JM, Thomsson KA, Bergstrom JH, et al. Composition and functional role of the mucus layers in the intestine. Cell Mol Life Sci 2011;68:3635-41.
52. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010;12: 319-30.
53. Bracarense AP, Lucioli J, Grenier B, Drociunas Pacheco G, Moll WD, Schatzmayr G, Oswald IP. Chronic ingestion of deoxynivalenol and fumonisin, alone or in interaction, induces morphological and immunological changes in the intestine of piglets. Br J Nutr 2012;107: 1776-86.
54. Zenhom M, Hyder A, de Vrese M, Heller KJ, Roeder T, Schrezenmeir J. Prebiotic oligosaccharides reduce proinflammatory cytokines in intestinal Caco-2 cells via activation of PPARγ and peptidoglycan recognition protein 3. J Nutr 2011;141:971-7.
55. Rossi O, Karczewski J, Stolte EH, Brummer RJ, van Nieuwenhoven MA, Meijerink M, van Neerven JR, van Ijzendoorn SC, van Baarlen P, Wells JM. Vectorial secretion of interleukin-8 mediates autocrine signalling in intestinal epithelial cells via apically located CXCR1. BMC Res Notes 2013;6:431.
56. Fusunyan RD, Quinn JJ, Ohno Y, MacDermott RP, Sanderson IR. Butyrate enhances interleukin (IL)-8 secretion by intestinal epithelial cells in response to IL-1beta and lipopolysaccharide. Pediatr Res 1998;43:84-90.
57. Keshavarzian A, Fusunyan RD, Jacyno M, Winship D, MacDermott RP, Sanderson IR. Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. Am J Gastroenterol 1999;94:704-12.
58. Sturm A, Baumgart DC, d'Heureuse JH, Hotz A, Wiedenmann B, Dignass AU. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine 2005;29:42-8.
59. Ortega-González M, Ocon B, Romero-Calvo I, Anzola A, Guadix E, Zarzuelo A, Suarez MD, Sanchez de Medina F, Martinez-Augustin O. Nondigestible oligosaccharides exert nonprebiotic effects on intestinal epithelial cells enhancing the immune response via activation of TLR4-NFkB. Mol Nutr Food Res 2014;58:384-93.
60. Vos AP, Haarman M, Buco A, Govers M, Knol J, Garssen J, Stahl B, Boehm G, M'Rabet L. A specific prebiotic oligosaccharide mixture stimulates delayed-type hypersensitivity in a murine influenza vaccination model. Int Immunopharmacol 2006;6:1277-86.
61. de Kivit S, Saeland E, Kraneveld AD, van de Kant HJ, Schouten B, van Esch BC, Knol J, Sprikkelman AB, van der Aa LB, Knippels LM, et al. Galectin-9 induced by dietary synbiotics is involved in suppression of allergic symptoms in mice and humans. Allergy 2012;67:343-52.
62. de Kivit S, Kraneveld AD, Knippels LM, van Kooyk Y, Garssen J, Willemsen LE. Intestinal epithelium-derived galectin-9 is involved in the immunomodulating effects of nondigestible oligosaccharides. J Innate Immun 2013;5:625-38.
63. Sagar S, Vos AP, Morgan ME, Garssen J, Georgiou NA, Boon L, Kraneveld AD, Folkerts G. The combination of Bifidobacterium breve with non-digestible oligosaccharides suppresses airway inflammation in a murine model for chronic asthma. Biochim Biophys Acta 2014;1842:573-83.
64. Villanacci V, Ceppa P, Tavani E, Vindigni C, Volta U. Coeliac disease: the histology report. Dig Liver Dis 2011;43(Suppl 4):S385-95.
65. Dickson BC, Streutker CJ, Chetty R. Coeliac disease: an update for pathologists. J Clin Pathol 2006;59:1008-16.
66. Pironi L, Bonvicini F, Gionchetti P, D'Errico A, Rizzello F, Corsini C, Foroni L, Gallinella G. Parvovirus b19 infection localized in the intestinal mucosa and associated with severe inflammatory bowel disease. J Clin Microbiol 2009;47:1591-5.